IP Library Granted Patent US 10,398,686
Granted Patent B2
US 10,398,686 · App. 15/457,545 · Granted Sep 3, 2019

Compositions of a polyorthoester and an aprotic solvent

Inventors: Thomas B. Ottoboni (Belmont, CA); Lee Ann Lynn Girotti (San Bruno, CA)
Assignee: Heron Therapeutics, Inc.
A61K31/4458A61K9/0024A61K31/439A61K31/445A61K31/485A61K47/10A61K47/14A61K47/18A61K47/20A61K47/22A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,398,686
App. No.
15/457,545
Granted
Sep 3, 2019
Kind
B2
Abstract

Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.

Claims (24)

1. A delivery system, comprising:

a polyorthoester;

dimethyl sulfoxide in which the polyorthoester is miscible to form a single phase; and

bupivacaine dispersed or solubilized in the single phase;

wherein the polyorthoester is a polyorthoester of Formula III;

where

A is R 1 or R 3 ,

R* is C1-4 alkyl,

n ranges from 5 to 1000,

R 1 is:

p and q are integers that vary from between about 1 to 20 and the average number of p or the average of the sum of p and q is between 1 and 7;

R 3 and R 6 are each independently:

x is an integer of 0-10;

R 5 is H or methyl, and

the fraction of A units that are of formula R 1 is between 0 and 25 mole percent.

2. The delivery system of claim 1 , wherein bupivacaine is dispersed in the single phase.

3. The delivery system of claim 1 , wherein bupivacaine is solubilized in the single phase.

4. The delivery system of claim 1 , wherein the delivery system has a viscosity of less than about 10,000 cP at 37° C.

5. The delivery system of claim 1 , where the polyorthoester has a molecular weight between about 1,000 and 10,000 daltons.

6. The delivery system of claim 1 , wherein bupivacaine is in an amount of about 1-20 percent by weight of the delivery system.

7. The delivery system of claim 6 , wherein bupivacaine is in an amount of about 2-5 percent by weight of the delivery system.

8. The delivery system of claim 1 , wherein dimethyl sulfoxide is in an amount of about 10-60 percent by weight of the delivery system.

9. The delivery system of claim 8 , wherein dimethyl sulfoxide is in an amount of about 10-20 percent by weight of the delivery system.

10. The delivery system of claim 1 , wherein the polyorthoester is in an amount of about 50-80 percent by weight of the delivery system.

Assignments (2)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 9, 2023
From: HERON THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 064546/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2017
From: OTTOBONI, THOMAS B.; GIROTTI, LEE ANN LYNN (NEE SCHILLINGER)
To: HERON THERAPEUTICS, INC.
Reel/Frame 042044/0081 →
Cited By (1)
US 12,318,376